NGM BIOPHARMACEUTICALS INC Quarterly Debt-to-equity in % from Q3 2019 to Q4 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Ngm Biopharmaceuticals Inc quarterly Debt-to-equity history and growth rate from Q3 2019 to Q4 2023.
  • Ngm Biopharmaceuticals Inc Debt-to-equity for the quarter ending December 31, 2023 was 14.9 %, a 10.8% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q4 2023 14.9 -1.81 -10.8% Dec 31, 2023
Q3 2023 16.2 -0.99 -5.76% Sep 30, 2023
Q2 2023 17.1 -0.08 -0.47% Jun 30, 2023
Q1 2023 17.1 +0.57 +3.45% Mar 31, 2023
Q4 2022 16.7 +1.34 +8.73% Dec 31, 2022
Q3 2022 17.2 +2.5 +17% Sep 30, 2022
Q2 2022 17.2 +2.59 +17.7% Jun 30, 2022
Q1 2022 16.5 +1.39 +9.18% Mar 31, 2022
Q4 2021 15.4 -0.47 -2.97% Dec 31, 2021
Q3 2021 14.7 -0.53 -3.48% Sep 30, 2021
Q2 2021 14.6 -0.03 -0.21% Jun 30, 2021
Q1 2021 15.2 +0.66 +4.56% Mar 31, 2021
Q4 2020 15.8 -7.3 -31.6% Dec 31, 2020
Q3 2020 15.2 -32.2 -67.9% Sep 30, 2020
Q2 2020 14.7 Jun 30, 2020
Q1 2020 14.5 Mar 31, 2020
Q4 2019 23.1 Dec 31, 2019
Q3 2019 47.4 Sep 30, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.